Check back for results at 8:30 a.m. ET
DUBLIN, Dec. 22, 2021 /PRNewswire/ — The "Proton Therapy Market Size, Share, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
The global Proton Therapy Market Size was US$ 68.1 Billion in 2021 and will surpass US$ 77 Billion by 2027.
The global proton therapy market will be growing rapidly due to a surging number of proton therapy centers across the world. And at the same time, many number of proton therapy centers are in the construction and in planning phases across the countries. In addition the other growth factors driving the global proton therapy market are advancement in the technology, surging prevalence of cancer patients worldwide. However to some extent, the factors such as huge investment required in this therapy as well as operations are the challenges which may hinder its market growth.
United States has the Largest Number of Proton Therapy Centers Globally
United States is the hub of proton therapy Industry having highest number of proton therapy centers globally. The United Kingdom is expected to launch advanced multi-room proton therapy centers owned by the NHS and Private Players in future. Similarly, the emerging countries are also escalating their demand for proton therapy in their regions as some cancer and cancer-related cases have been surging and will surely boost the growth of this market during the forecast period. As per our analysis, Global Proton therapy will grow at a CAGR of 2.07% during 2021-2027.
Worldwide Proton Therapy Market Insight:
According to the American Cancer Society, about 1.8 million new cancer cases are diagnosed and around 606,520 cancer deaths happened in the United States in the year 2020.
Europe is also a big market for proton therapy due to growing use of tobacco.
According to Eurostat, 1 in 4 EU citizens over 15 years old (24%) is a tobacco smoker.
The World Health Organization stated that nearly 70% deaths due to cancer occur in low and middle income countries like Asia Pacific and this region country is expected to enlarge at a higher growth rate because of the growing awareness among people, large target population, and increase in health care expenditure.
COVID-19 Impact on Proton Therapy Industry
Despite the outbreak of COVID-19 around the world, the proton therapy market has grown at a constant rate. Proton therapy radiation therapy was stopped for a brief round of period, but it was resumed again for patients. To take care of the regular patient and radiation therapies patients, in the United States many processes has been finalized to help the patients with therapies. As such many implementation and algorithms have been carried out during the period to safeguard the radiation patients from COVID-19. We expect the post-pandemic recovery for the global proton therapy industry would surge during the forecast period.
This report provides a detailed analysis of Global Neonatal Intensive Care Industry.
Proton Therapy Market & Patient Numbers breakup of 12 Countries
Key Topics Covered:
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
5. Global Proton Therapy Market (Actual & Potential)
5.1 Global Proton Therapy Market
5.2 Global Potential Proton Therapy Market
6. Global Proton Therapy Patient Number & Forecast (Actual and Potential)
6.1 Patients Treated with Proton Therapy Actual Numbers
6.2 Patients with Proton Therapy Potential Numbers
7. Market Share – Global Proton Therapy
7.1 By Region
7.2 By Countries
8. Global Proton Therapy Centers List
8.1 Operational Facilities – Global Proton Therapy Centers
8.2 Under-Construction Stage – Global Proton Therapy Centers
8.3 Planning Phase – Global Proton Therapy Centers
9. United States Proton Therapy Market, Patient Numbers
10. Asia Proton Therapy Market Share – by Countries
11. Asia Proton Therapy Market, Numbers & Forecast
12. Asia – Proton Therapy Market, Patient Numbers (Country wise)
13. Asia List of Proton Therapy Centers
14. Europe Proton Therapy Market, Numbers & Forecast
15. Europe Proton Therapy Market Share – by Countries
16. Europe – Proton Therapy Market, Patient Numbers (Country wise)
17. Reimbursement Policy
17.1 Reimbursement Policies for Patients
17.2 Reimbursement for Institutions, Stakeholders and Manufacturers
18. Components of a Standard Proton Therapy Center
20. Company Analysis
IBA Proton Therapy
Varian Medical Systems
For more information about this report visit https://www.researchandmarkets.com/r/vd71ow
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/worldwide-proton-therapy-market-outlook-to-2027-company-profiles-of-of-key-players-iba-proton-therapy-varian-medical-systems-and-elekta-301449771.html
SOURCE Research and Markets
Truck Meet was notorious for noise, behavior and traffic issues since its inception eight years ago.
Allakos has deep pockets, but its market cap now is roughly equal to its $500 million or so in cash, and it has a new 10-year, $69-per-square-foot lease on its books in San Carlos.
What happened Shares of Moderna (NASDAQ: MRNA) fell 6.3% on Wednesday after the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization for Pfizer's (NYSE: PFE) oral COVID-19 treatment, Paxlovid.
(Bloomberg) — Exxon Mobil Corp. is working to extinguish a fire at its Baytown facility in Texas, the fourth-largest refinery in the U.S. Most Read from BloombergOmicron May Double Risk of Getting Infected on Planes, IATA SaysOmicron Has 80% Lower Risk of Hospitalization in South AfricaOmicron Hospitalization Risk Is Far Below Delta’s in Two StudiesJersey Shore Town Beats Florida Locales as Zillow Retirement HotspotBiden Extends Student-Loan Payment Pause After Virus SurgesFour people have been
What happened Shares of Teladoc Health (NYSE: TDOC) were falling 3.2% as of 2:42 p.m. ET on Wednesday. The decline appeared to be linked to reduced concerns about the impact of the coronavirus omicron variant.
Acadia Pharmaceuticals (NASDAQ: ACAD), a mid-cap biotech company that focuses on neuroscience therapies, saw its shares rise 10.6% on Wednesday. It plans to resubmit its supplemental New Drug Application (sNDA) for Nuplazid (pimavanserin), as a treatment for hallucinations and delusions associated with dementia. The company said it planned the resubmission, based on clinical data, for the first quarter of next year.
Whether GE ultimately continues as one company or three, it needs to stop offshoring manufacturing jobs.
(Bloomberg) — Intel Corp.’s global push to increase capacity will include adding facilities in France and Italy, as well as putting a major production site in Germany, according to people familiar with negotiations. Most Read from BloombergOmicron May Double Risk of Getting Infected on Planes, IATA SaysOmicron Has 80% Lower Risk of Hospitalization in South AfricaOmicron Hospitalization Risk Is Far Below Delta’s in Two StudiesJersey Shore Town Beats Florida Locales as Zillow Retirement HotspotBi
As the cannabis industry starts to develop and overcome major challenges, find out what's in store for 2022.
These supercharged income stocks, with yields ranging from 8.6% to 13.2%, could be big winners in the new year.
Dr. Owais Durrani, an emergency medicine physician, joins Yahoo Finance to discuss what Pfizer’s COVID-19 pill and Biden’s winter plan to address rising Omicron cases means in the fight against the coronavirus.
Tuesday was the Winter Solstice, our darkest day and longest night before the sun begins its slow ascent higher into the sky again.
Workplace stress is rampant and resignations have risen. Employers are struggling to stop employees from leaving and to boost morale. Some are trying four-day workweeks, mandatory vacation days and other new ways of working.
The Paxlovid pill is the first Covid-19 drug cleared in the U.S. that newly infected patients can now take at home to stay out of the hospital.
Is AbbVie stock a buy as shares retake their key moving averages on strong third-quarter earnings? Is ABBV stock a buy right now?
(Bloomberg) — China’s reaffirmation of a long-term goal to be almost entirely self-sufficient in pork production means it will keep scooping up global grain supplies to feed the world’s largest pig herd. Most Read from BloombergOmicron May Double Risk of Getting Infected on Planes, IATA SaysOmicron Has 80% Lower Risk of Hospitalization in South AfricaOmicron Hospitalization Risk Is Far Below Delta’s in Two StudiesJersey Shore Town Beats Florida Locales as Zillow Retirement HotspotBiden Extends
The small company, formed as the Covid pandemic started to take hold in February 2020, could take its oral drug into a late-stage clinical trial as early as the first half of next year.
In 2020, most people had to cancel their vacation plans because of the COVID pandemic. But this year, travel has picked back up dramatically thanks to vaccinations and ongoing mask requirements. For the past two months, airports in the U.S. have seen upwards of two million passengers pass through each day, according to the Transportation Security Administration (TSA). That's a sharp increase from the 500,000 to 900,000 air travelers seen each day at this same time last year. Unfortunately, a hig
BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into a Master Service Agreement with PRC Clinical, a contract research organization (CRO), to conduct BioRestorative's Phase 2 trial. According to the agreement, PRC Clinical will manage BioRestorative's Phase 2 clinical study of BRTX-100, the Company's lead clinical product to treat chronic lumbar disc disease. The Company's lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchy
Real estate investment trusts (REITs) are publicly traded companies that allow individual investors to buy shares in real estate portfolios that receive income from a variety of properties. They allow investors to easily invest in the real estate sector, which includes companies that own, develop, and manage residential, commercial, and industrial properties.